uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.23 | Q16 | What Protein therapies have been approved by the FDA to treat Aplastic anemia? | There are no drug Protein therapies approved to treat Aplastic anemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aplastic anemia" OR LOWER(mesh_heading) = "aplastic anemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.359 | Q16 | What Small molecule therapies have been approved by the FDA to treat Behcet's syndrome? | There are no drug Small molecule therapies approved to treat Behcet's syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "behcet's syndrome" OR LOWER(mesh_heading) = "behcet's syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1486 | Q16 | What Small molecule therapies have been approved by the FDA to treat pleural effusion? | There are no drug Small molecule therapies approved to treat pleural effusion. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pleural effusion" OR LOWER(mesh_heading) = "pleural effusion") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.343 | Q16 | What Small molecule therapies have been approved by the FDA to treat Aphasia? | There are no drug Small molecule therapies approved to treat Aphasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aphasia" OR LOWER(mesh_heading) = "aphasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.435 | Q16 | What Small molecule therapies have been approved by the FDA to treat Eye Burns? | There are no drug Small molecule therapies approved to treat Eye Burns. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eye burns" OR LOWER(mesh_heading) = "eye burns") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.477 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hemangioma, Cavernous, Central Nervous System? | There are no drug Small molecule therapies approved to treat Hemangioma, Cavernous, Central Nervous System. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemangioma, cavernous, central nervous system" OR LOWER(mesh_heading) = "hemangioma, cavernous, central nervous system") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.219 | Q16 | What Protein therapies have been approved by the FDA to treat metabolic syndrome? | There are no drug Protein therapies approved to treat metabolic syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "metabolic syndrome" OR LOWER(mesh_heading) = "metabolic syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.919 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic myelogenous leukemia? | There are 6 Small molecule therapy drugs that are approved to treat chronic myelogenous leukemia which are as follows: Bosutinib, Dasatinib, Imatinib Mesylate, Nilotinib Hydrochloride Monohydrate, Asciminib Hydrochloride, and Ponatinib Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic myelogenous leukemia" OR LOWER(mesh_heading) = "chronic myelogenous leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710887', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_710908', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_710929', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_710950', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_710971', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_710992', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711013', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711034', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711055', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711076', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711097', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711118', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711139', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711160', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711181', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711202', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711223', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711244', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711265', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711286', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711307', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711328', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711349', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711370', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711391', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711412', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711433', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711454', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711475', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711496', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711517', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711538', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711559', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711580', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711601', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711622', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711643', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711664', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711685', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711706', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711727', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711748', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711769', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711790', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711811', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711832', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711853', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711874', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711895', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711916', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711937', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711958', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_711979', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712000', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712021', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712042', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712063', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712084', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712105', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712126', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712147', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712168', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712189', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712210', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712231', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712252', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712273', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712294', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712315', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712336', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712357', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712378', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712399', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712420', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712441', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712462', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712483', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712504', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712525', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712546', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712567', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712588', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712609', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712630', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712651', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712672', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712693', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712714', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712735', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712756', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712777', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712798', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712819', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712840', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712861', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712882', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712903', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712924', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712945', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_712966', 'drugName': 'Bosutinib', 'tradeNames_list': "['Bosulif']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000254087', 'approvedSymbol': 'LYN', 'approvedName': 'LYN proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1236 | Q16 | What Small molecule therapies have been approved by the FDA to treat knee injury? | There are no drug Small molecule therapies approved to treat knee injury. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "knee injury" OR LOWER(mesh_heading) = "knee injury") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1408 | Q16 | What Small molecule therapies have been approved by the FDA to treat oral submucous fibrosis? | There are no drug Small molecule therapies approved to treat oral submucous fibrosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oral submucous fibrosis" OR LOWER(mesh_heading) = "oral submucous fibrosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1019 | Q16 | What Small molecule therapies have been approved by the FDA to treat endometrial carcinoma? | There are no drug Small molecule therapies approved to treat endometrial carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "endometrial carcinoma" OR LOWER(mesh_heading) = "endometrial carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1714 | Q16 | What Small molecule therapies have been approved by the FDA to treat type 1 diabetes mellitus? | There are no drug Small molecule therapies approved to treat type 1 diabetes mellitus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "type 1 diabetes mellitus" OR LOWER(mesh_heading) = "type 1 diabetes mellitus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.94 | Q16 | What Protein therapies have been approved by the FDA to treat aortic stenosis? | There are no drug Protein therapies approved to treat aortic stenosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aortic stenosis" OR LOWER(mesh_heading) = "aortic stenosis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1016 | Q16 | What Small molecule therapies have been approved by the FDA to treat emphysema? | There are 8 Small molecule therapy drugs that are approved to treat emphysema which are as follows: Budesonide, Fluticasone Propionate, Umeclidinium Bromide, Aclidinium Bromide, Ipratropium Bromide, Tiotropium Bromide, Olodaterol Hydrochloride, and Indacaterol Maleate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "emphysema" OR LOWER(mesh_heading) = "emphysema") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222388', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222433', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222478', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222523', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222568', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222613', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222658', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222703', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222748', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222793', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222838', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222883', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222928', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_222973', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223018', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223063', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223108', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223153', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223198', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223243', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223288', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223333', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223378', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223423', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223468', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223513', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223558', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223603', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223648', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223693', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223738', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223783', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223828', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223873', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223918', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_223963', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224008', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224053', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224098', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224143', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224188', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224233', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224278', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224323', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224368', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224413', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224458', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224503', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224548', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224593', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224638', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224683', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224728', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224773', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224818', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224863', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224908', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224953', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_224998', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225043', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225088', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225133', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225178', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225223', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225268', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225313', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225358', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_225403', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232395', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232422', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232449', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232476', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232503', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232530', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232557', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232584', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232611', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232638', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232665', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232692', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232719', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232746', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232773', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232800', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232827', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232854', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232881', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232908', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232935', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232962', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_232989', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233016', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233043', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233070', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233097', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233124', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233151', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233178', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233205', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}, {'UUID': 'DrugTargetsIndication121923_text_233232', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1079 | Q16 | What Small molecule therapies have been approved by the FDA to treat follicular lymphoma? | There are 4 Small molecule therapy drugs that are approved to treat follicular lymphoma which are as follows: Umbralisib Tosylate, Copanlisib Hydrochloride, Duvelisib, and Tazemetostat Hydrobromide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "follicular lymphoma" OR LOWER(mesh_heading) = "follicular lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_744622', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744637', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744652', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744667', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744682', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744697', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744712', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744727', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744742', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744757', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744772', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744787', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744802', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744817', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744832', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744847', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744862', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744877', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744892', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744907', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744922', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744937', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744952', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744967', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744982', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744997', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745012', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745027', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745042', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745057', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745072', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745087', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745102', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745117', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745132', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745147', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745162', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745177', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745192', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745207', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745222', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745237', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745252', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745267', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745282', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858316', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858325', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858334', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858343', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858352', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858361', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858370', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858379', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858740', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858760', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858780', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858800', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858820', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858840', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858860', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858880', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858900', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858920', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858940', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858960', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858980', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859000', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859020', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859040', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859060', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859080', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859100', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859120', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859140', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859160', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859180', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859200', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859220', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859240', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859260', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859280', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095390', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095393', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095396', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095399', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095402', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095405', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095408', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095411', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095414', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095417', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095420', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095423', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095426', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095429', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095432', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095435', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095438', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095441', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1095444', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106462', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1101 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastrointestinal disease? | Glycopyrrolate is the only Small molecule therapy approved by the FDA to treat gastrointestinal disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastrointestinal disease" OR LOWER(mesh_heading) = "gastrointestinal disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857490', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857499', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857508', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857517', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857526', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857535', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857544', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857553', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857562', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857571', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857580', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857589', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857598', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857607', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857616', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857625', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857634', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857643', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857652', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857661', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857670', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857679', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857688', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857697', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857706', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857715', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857724', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857733', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857742', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857751', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857760', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857769', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857778', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}, {'UUID': 'DrugTargetsIndication121923_text_857787', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000168539', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1399 | Q16 | What Small molecule therapies have been approved by the FDA to treat open-angle glaucoma? | There are 7 Small molecule therapy drugs that are approved to treat open-angle glaucoma which are as follows: Brimonidine Tartrate, Netarsudil Dimesylate, Latanoprostene Bunod, Latanoprost, Bimatoprost, Travoprost, and Tafluprost. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "open-angle glaucoma" OR LOWER(mesh_heading) = "open-angle glaucoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034053', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034068', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034083', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034098', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034113', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034128', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034143', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034158', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034173', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034188', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034203', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034218', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034233', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034248', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034263', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034278', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034293', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034308', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034323', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034338', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034353', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034368', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034383', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034398', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034413', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034428', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034443', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034458', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034473', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034488', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034503', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034518', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034533', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034548', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034563', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034578', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034593', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034608', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034623', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034638', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034653', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034668', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034683', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034698', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034713', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034728', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034743', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034758', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034773', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034788', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034803', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034818', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034833', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034848', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034863', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034878', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034893', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034908', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034923', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034938', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034953', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034968', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034983', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1034998', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035013', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035028', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035043', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035058', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035073', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035088', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035103', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035118', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035133', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035148', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035163', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035178', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035193', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035208', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035223', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035238', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035253', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035268', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035283', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1035298', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076324', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076326', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076328', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076330', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076332', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076334', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076336', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076338', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076340', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076342', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076344', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076346', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076348', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076350', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076352', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}, {'UUID': 'DrugTargetsIndication121923_text_1076354', 'drugName': 'Netarsudil Dimesylate', 'tradeNames_list': "['Rhopressa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.701 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute graft vs. host disease? | There are no drug Small molecule therapies approved to treat acute graft vs. host disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute graft vs. host disease" OR LOWER(mesh_heading) = "acute graft vs. host disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1578 | Q16 | What Small molecule therapies have been approved by the FDA to treat restless legs syndrome? | There are 4 Small molecule therapy drugs that are approved to treat restless legs syndrome which are as follows: Pramipexole Dihydrochloride, Rotigotine, Gabapentin Enacarbil, and Gabapentin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "restless legs syndrome" OR LOWER(mesh_heading) = "restless legs syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199708', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199712', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199716', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199720', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199724', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199728', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199732', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199736', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199740', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199744', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199748', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199752', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199756', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199760', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199764', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199768', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199772', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199776', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199780', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199784', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199788', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199792', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199796', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199800', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199804', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199808', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199812', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199816', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199820', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199824', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199828', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199832', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199836', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199840', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199844', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199848', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199852', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199856', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199860', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199864', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199868', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_199872', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200711', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200716', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200721', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200726', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200731', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200736', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200741', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200746', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200751', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200756', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200761', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200766', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200771', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200776', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200781', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200786', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200791', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200796', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200801', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200806', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200811', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200816', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200821', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200826', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200831', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200836', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200841', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200846', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200851', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200856', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200861', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200866', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200871', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200876', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200881', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200886', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200891', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200896', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200901', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200906', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200911', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200916', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200921', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200926', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200931', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200936', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200941', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200946', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200951', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200956', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200961', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200966', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200971', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200976', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200981', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200986', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200991', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_200996', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1004 | Q16 | What Small molecule therapies have been approved by the FDA to treat drug dependence? | There are 7 Small molecule therapy drugs that are approved to treat drug dependence which are as follows: Dextroamphetamine, Lisdexamfetamine Dimesylate, Morphine Sulfate, Buprenorphine, Tramadol Hydrochloride, Oxycodone, and Hydromorphone Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "drug dependence" OR LOWER(mesh_heading) = "drug dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418360', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418373', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418386', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418399', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418412', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418425', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418438', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418451', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418464', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418477', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418490', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418503', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418516', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418529', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418542', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418555', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418568', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418581', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418594', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418607', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418620', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418633', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418646', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418659', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418672', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418685', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418698', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418711', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418724', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418737', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418750', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418763', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418776', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418789', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418802', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418815', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418828', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418841', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418854', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418867', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418880', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418893', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418906', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418919', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418932', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418945', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418958', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418971', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418984', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_418997', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419010', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419023', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419036', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419049', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419062', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419075', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419088', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419101', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419114', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419127', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419138', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419149', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419160', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419171', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419182', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419193', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419204', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419215', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419226', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419237', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419248', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419259', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419270', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419281', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419292', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419303', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419314', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419325', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419336', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419347', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419358', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419369', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419380', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419391', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419402', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419413', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419424', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419435', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419446', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419457', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419468', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419479', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419490', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419501', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419512', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419523', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419534', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419545', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419556', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}, {'UUID': 'DrugTargetsIndication121923_text_419567', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.154 | Q16 | What Protein therapies have been approved by the FDA to treat enuresis? | Desmopressin Acetate is the only Protein therapy approved by the FDA to treat enuresis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "enuresis" OR LOWER(mesh_heading) = "enuresis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694400', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694411', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694422', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694433', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694444', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694455', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694466', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694477', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694488', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694499', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694510', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694521', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694532', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694543', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694554', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694565', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694576', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694587', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694598', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694609', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694620', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694631', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694642', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694653', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694664', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694675', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694686', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694697', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694708', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694719', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694730', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694741', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694752', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694763', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694774', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694785', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694796', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694807', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694818', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694829', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694840', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694851', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694862', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694873', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694884', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694895', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694906', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694917', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694928', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694939', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694950', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694961', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694972', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694983', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_694994', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695005', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695016', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695027', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695038', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695049', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695060', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695071', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}, {'UUID': 'DrugTargetsIndication121923_text_695082', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1108 | Q16 | What Small molecule therapies have been approved by the FDA to treat giant cell tumor? | There are no drug Small molecule therapies approved to treat giant cell tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "giant cell tumor" OR LOWER(mesh_heading) = "giant cell tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1518 | Q16 | What Small molecule therapies have been approved by the FDA to treat premenstrual tension? | There are no drug Small molecule therapies approved to treat premenstrual tension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "premenstrual tension" OR LOWER(mesh_heading) = "premenstrual tension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1761 | Q16 | What Small molecule therapies have been approved by the FDA to treat wet macular degeneration? | There are no drug Small molecule therapies approved to treat wet macular degeneration. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "wet macular degeneration" OR LOWER(mesh_heading) = "wet macular degeneration") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.797 | Q16 | What Small molecule therapies have been approved by the FDA to treat atrial flutter? | There are no drug Small molecule therapies approved to treat atrial flutter. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "atrial flutter" OR LOWER(mesh_heading) = "atrial flutter") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.584 | Q16 | What Small molecule therapies have been approved by the FDA to treat Parkinsonism? | Amantadine Hydrochloride is the only Small molecule therapy approved by the FDA to treat Parkinsonism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "parkinsonism" OR LOWER(mesh_heading) = "parkinsonism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_441018', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441032', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441046', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441060', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441074', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441088', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441102', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441116', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441130', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441144', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441158', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441172', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441186', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441200', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441214', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441228', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441242', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441256', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441270', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441284', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441298', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441312', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441326', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441340', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441354', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441368', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441382', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441396', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441410', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441424', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441438', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441452', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441466', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441480', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441494', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441508', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441522', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441536', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441550', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441564', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441578', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441592', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441606', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441620', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441634', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441648', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441662', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441676', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441690', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441704', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441718', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441732', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441746', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441760', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441774', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441788', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441802', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441816', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441830', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441844', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441858', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441872', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441886', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441900', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441914', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441928', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441942', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441956', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441970', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441984', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_441998', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442012', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442026', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442040', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442054', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442068', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442082', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442096', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442110', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442124', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442138', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442152', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442166', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442180', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442194', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442208', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442222', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442236', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442250', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442264', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442278', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442292', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442306', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442320', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442334', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442348', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442362', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442376', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442390', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}, {'UUID': 'DrugTargetsIndication121923_text_442404', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.708 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute myeloblastic leukemia without maturation? | There are no drug Small molecule therapies approved to treat acute myeloblastic leukemia without maturation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute myeloblastic leukemia without maturation" OR LOWER(mesh_heading) = "acute myeloblastic leukemia without maturation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1221 | Q16 | What Small molecule therapies have been approved by the FDA to treat iritis? | There are 2 Small molecule therapy drugs that are approved to treat iritis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "iritis" OR LOWER(mesh_heading) = "iritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217669', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_217877', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_218085', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_218293', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_218501', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_218709', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_218917', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_219125', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_219333', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_219541', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_219749', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_219957', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_220165', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_220373', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_220581', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_220789', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_226366', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_226651', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_226936', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_227221', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_227506', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_227791', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_228076', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_228361', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_228646', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_228931', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_229216', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_229501', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_229786', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_230071', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_230356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_230641', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_230926', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_231211', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_231496', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_231781', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_232066', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}, {'UUID': 'DrugTargetsIndication121923_text_232351', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1471 | Q16 | What Small molecule therapies have been approved by the FDA to treat persistent fetal circulation syndrome? | There are no drug Small molecule therapies approved to treat persistent fetal circulation syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "persistent fetal circulation syndrome" OR LOWER(mesh_heading) = "persistent fetal circulation syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1270 | Q16 | What Small molecule therapies have been approved by the FDA to treat lymphocytic colitis? | There are no drug Small molecule therapies approved to treat lymphocytic colitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphocytic colitis" OR LOWER(mesh_heading) = "lymphocytic colitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.491 | Q16 | What Small molecule therapies have been approved by the FDA to treat Histiocytosis? | There are no drug Small molecule therapies approved to treat Histiocytosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "histiocytosis" OR LOWER(mesh_heading) = "histiocytosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.563 | Q16 | What Small molecule therapies have been approved by the FDA to treat Nausea? | There are 5 Small molecule therapy drugs that are approved to treat Nausea which are as follows: Palonosetron Hydrochloride, Granisetron, Ondansetron, Aprepitant, and Dronabinol. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nausea" OR LOWER(mesh_heading) = "nausea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205491', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205494', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205497', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205500', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205503', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205506', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205509', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205512', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205515', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205518', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205521', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205524', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205527', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205530', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205533', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205536', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205539', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205542', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205545', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205548', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205551', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205554', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205557', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205560', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205563', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205566', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205569', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205572', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205575', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205578', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205581', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205584', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205587', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205590', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205593', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205596', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205599', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205602', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205605', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205608', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205611', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205614', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205617', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205620', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205623', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205626', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205629', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205632', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205635', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205638', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205641', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205644', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205647', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205650', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205653', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205656', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205659', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205662', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205665', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205668', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205671', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205674', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205677', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205680', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205683', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205686', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205689', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205692', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205695', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205698', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205701', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205704', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205707', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205710', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205713', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205716', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205719', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205722', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205725', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205728', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205731', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205734', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205737', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205740', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205749', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205753', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205763', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205767', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205777', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205781', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205791', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205795', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205805', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205809', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205819', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205823', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205858', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}, {'UUID': 'DrugTargetsIndication121923_text_205861', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205863', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205898', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1150 | Q16 | What Small molecule therapies have been approved by the FDA to treat hilar cholangiocarcinoma? | There are no drug Small molecule therapies approved to treat hilar cholangiocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hilar cholangiocarcinoma" OR LOWER(mesh_heading) = "hilar cholangiocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1128 | Q16 | What Small molecule therapies have been approved by the FDA to treat hemangioblastoma? | Belzutifan is the only Small molecule therapy approved by the FDA to treat hemangioblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemangioblastoma" OR LOWER(mesh_heading) = "hemangioblastoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192115', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116016', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemangioblastoma', 'efo_term': 'hemangioblastoma'}, {'UUID': 'DrugTargetsIndication121923_text_1192123', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116016', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemangioblastoma', 'efo_term': 'hemangioblastoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.809 | Q16 | What Small molecule therapies have been approved by the FDA to treat bacterial meningitis? | There are no drug Small molecule therapies approved to treat bacterial meningitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bacterial meningitis" OR LOWER(mesh_heading) = "bacterial meningitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.516 | Q16 | What Small molecule therapies have been approved by the FDA to treat Intervertebral Disc Displacement? | There are no drug Small molecule therapies approved to treat Intervertebral Disc Displacement. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intervertebral disc displacement" OR LOWER(mesh_heading) = "intervertebral disc displacement") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.637 | Q16 | What Small molecule therapies have been approved by the FDA to treat Strabismus? | There are no drug Small molecule therapies approved to treat Strabismus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "strabismus" OR LOWER(mesh_heading) = "strabismus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1297 | Q16 | What Small molecule therapies have been approved by the FDA to treat mediastinal cancer? | There are no drug Small molecule therapies approved to treat mediastinal cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mediastinal cancer" OR LOWER(mesh_heading) = "mediastinal cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1574 | Q16 | What Small molecule therapies have been approved by the FDA to treat respiratory depression? | There are no drug Small molecule therapies approved to treat respiratory depression. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "respiratory depression" OR LOWER(mesh_heading) = "respiratory depression") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1159 | Q16 | What Small molecule therapies have been approved by the FDA to treat hyperlipidemia? | There are 7 Small molecule therapy drugs that are approved to treat hyperlipidemia which are as follows: Sitagliptin Phosphate, Amlodipine Besylate, Ezetimibe, Simvastatin, Rosuvastatin Calcium, Pitavastatin Calcium, and Pitavastatin Magnesium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperlipidemia" OR LOWER(mesh_heading) = "hyperlipidemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933043', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933049', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933055', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933061', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933067', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933073', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933079', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933085', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933091', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933097', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933103', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933109', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933115', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933121', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933127', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933133', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933139', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933145', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933151', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933157', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933163', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933169', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933175', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933181', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933187', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933193', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933199', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933205', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933211', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933217', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933223', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933229', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933235', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933241', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933247', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933253', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933259', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933265', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933271', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933277', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933283', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933289', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933295', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933301', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_933307', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043672', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043686', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043700', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043714', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043728', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043742', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043756', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043770', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043784', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043798', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043812', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043826', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043840', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043854', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043868', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043882', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043896', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043910', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043924', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043938', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043952', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043966', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043980', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043994', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097328', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097349', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097370', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097391', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097412', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1103800', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1103904', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104008', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104112', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104135', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104152', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104169', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104186', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104203', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104220', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104237', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104254', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104258', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104262', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104266', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104270', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104274', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104278', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104282', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104286', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104290', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104294', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104298', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104302', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104304', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}, {'UUID': 'DrugTargetsIndication121923_text_1104306', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.798 | Q16 | What Small molecule therapies have been approved by the FDA to treat atrioventricular block? | There are no drug Small molecule therapies approved to treat atrioventricular block. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "atrioventricular block" OR LOWER(mesh_heading) = "atrioventricular block") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.117 | Q16 | What Protein therapies have been approved by the FDA to treat carcinoid tumor? | Octreotide Acetate is the only Protein therapy approved by the FDA to treat carcinoid tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "carcinoid tumor" OR LOWER(mesh_heading) = "carcinoid tumor") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1042018', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042039', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042060', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042081', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042102', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042123', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042144', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042165', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042186', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042207', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042228', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042249', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042270', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042291', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042312', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042333', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042354', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042375', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042396', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042417', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042438', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042459', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042480', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042501', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042522', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042543', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042564', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042585', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042606', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042627', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042648', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042669', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042690', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042711', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042732', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042753', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042774', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042795', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042816', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042837', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042858', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042879', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042900', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042921', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1042942', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoid Tumor', 'efo_term': 'carcinoid tumor'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.746 | Q16 | What Small molecule therapies have been approved by the FDA to treat alveolar soft part sarcoma? | There are no drug Small molecule therapies approved to treat alveolar soft part sarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alveolar soft part sarcoma" OR LOWER(mesh_heading) = "alveolar soft part sarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1090 | Q16 | What Small molecule therapies have been approved by the FDA to treat gambling behaviour? | There are no drug Small molecule therapies approved to treat gambling behaviour. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gambling behaviour" OR LOWER(mesh_heading) = "gambling behaviour") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.838 | Q16 | What Small molecule therapies have been approved by the FDA to treat brain disease? | There are no drug Small molecule therapies approved to treat brain disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brain disease" OR LOWER(mesh_heading) = "brain disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.120 | Q16 | What Protein therapies have been approved by the FDA to treat cardiovascular disease? | There are no drug Protein therapies approved to treat cardiovascular disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cardiovascular disease" OR LOWER(mesh_heading) = "cardiovascular disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.660 | Q16 | What Small molecule therapies have been approved by the FDA to treat Thyroid Gland Undifferentiated (Anaplastic) Carcinoma? | There are no drug Small molecule therapies approved to treat Thyroid Gland Undifferentiated (Anaplastic) Carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thyroid gland undifferentiated (anaplastic) carcinoma" OR LOWER(mesh_heading) = "thyroid gland undifferentiated (anaplastic) carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1675 | Q16 | What Small molecule therapies have been approved by the FDA to treat synovitis? | There are 2 Small molecule therapy drugs that are approved to treat synovitis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "synovitis" OR LOWER(mesh_heading) = "synovitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217658', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_217866', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218074', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218282', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218490', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218698', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218906', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219114', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219322', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219530', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219738', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219946', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220154', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220362', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220570', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220778', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_226353', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_226638', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_226923', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_227208', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_227493', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_227778', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228063', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228348', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228633', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228918', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_229203', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_229488', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_229773', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230058', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230343', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230628', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230913', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_231198', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_231483', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_231768', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_232053', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}, {'UUID': 'DrugTargetsIndication121923_text_232338', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.639 | Q16 | What Small molecule therapies have been approved by the FDA to treat Stridor? | There are no drug Small molecule therapies approved to treat Stridor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stridor" OR LOWER(mesh_heading) = "stridor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.372 | Q16 | What Small molecule therapies have been approved by the FDA to treat Brugada syndrome? | There are no drug Small molecule therapies approved to treat Brugada syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brugada syndrome" OR LOWER(mesh_heading) = "brugada syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.270 | Q16 | What Protein therapies have been approved by the FDA to treat primary short bowel syndrome? | Teduglutide is the only Protein therapy approved by the FDA to treat primary short bowel syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary short bowel syndrome" OR LOWER(mesh_heading) = "primary short bowel syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149449', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1149458', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1149467', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1149476', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1149485', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1149494', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.659 | Q16 | What Small molecule therapies have been approved by the FDA to treat Thymoma? | There are no drug Small molecule therapies approved to treat Thymoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thymoma" OR LOWER(mesh_heading) = "thymoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.943 | Q16 | What Small molecule therapies have been approved by the FDA to treat colorectal adenoma? | There are no drug Small molecule therapies approved to treat colorectal adenoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colorectal adenoma" OR LOWER(mesh_heading) = "colorectal adenoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.830 | Q16 | What Small molecule therapies have been approved by the FDA to treat bone fracture? | There are no drug Small molecule therapies approved to treat bone fracture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bone fracture" OR LOWER(mesh_heading) = "bone fracture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.874 | Q16 | What Small molecule therapies have been approved by the FDA to treat cataract? | There are 4 Small molecule therapy drugs that are approved to treat cataract which are as follows: Nepafenac, Diclofenac, Ketorolac Tromethamine, and Bromfenac Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cataract" OR LOWER(mesh_heading) = "cataract") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828587', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828592', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828597', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828602', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828607', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828612', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828617', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828622', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828627', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828632', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828637', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_828642', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_836984', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837014', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837044', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837074', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837104', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837134', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837164', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837194', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837224', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837254', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837284', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837314', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837344', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837374', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837404', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837434', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837464', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837494', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837524', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837554', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837584', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837614', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837644', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837674', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837704', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837734', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837764', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837794', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837824', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837854', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837884', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837914', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837944', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_837974', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_838004', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_838034', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841770', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841786', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841802', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841818', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841834', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841850', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841866', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841882', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841898', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841914', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841930', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841946', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841962', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841978', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_841994', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842010', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842026', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842042', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842058', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842074', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842090', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842106', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842122', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842138', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842154', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842170', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842186', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842202', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842218', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842234', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842250', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842266', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842544', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842547', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842550', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842553', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842556', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842559', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842562', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842565', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842568', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842571', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842574', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842577', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842580', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842583', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842586', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842589', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842592', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842595', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842598', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}, {'UUID': 'DrugTargetsIndication121923_text_842601', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.47 | Q16 | What Protein therapies have been approved by the FDA to treat Hypoglycemia? | Glucagon is the only Protein therapy approved by the FDA to treat Hypoglycemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypoglycemia" OR LOWER(mesh_heading) = "hypoglycemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_968292', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}, {'UUID': 'DrugTargetsIndication121923_text_968300', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}, {'UUID': 'DrugTargetsIndication121923_text_968308', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}, {'UUID': 'DrugTargetsIndication121923_text_968316', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}, {'UUID': 'DrugTargetsIndication121923_text_968324', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}, {'UUID': 'DrugTargetsIndication121923_text_968332', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}, {'UUID': 'DrugTargetsIndication121923_text_968340', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}, {'UUID': 'DrugTargetsIndication121923_text_968348', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000215644', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1543 | Q16 | What Small molecule therapies have been approved by the FDA to treat psoriatic arthritis? | There are 4 Small molecule therapy drugs that are approved to treat psoriatic arthritis which are as follows: Prednisone, Dexamethasone, Apremilast, and Tofacitinib Citrate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "psoriatic arthritis" OR LOWER(mesh_heading) = "psoriatic arthritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217640', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_217848', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218056', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218264', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218472', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218680', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218888', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219096', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219304', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219512', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219720', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219928', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220136', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220344', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220552', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220760', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_226334', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_226619', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_226904', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_227189', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_227474', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_227759', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228044', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228329', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228614', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228899', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_229184', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_229469', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_229754', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230039', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230324', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230609', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230894', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_231179', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_231464', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_231749', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_232034', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_232319', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696794', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696822', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696850', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696878', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696906', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696934', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696962', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_696990', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697018', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697046', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697074', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697102', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697130', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697158', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697186', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697214', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697242', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697270', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697298', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697326', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697354', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697382', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697410', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697438', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697466', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697494', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697522', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697550', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697578', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697606', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697634', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697662', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697690', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697718', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697746', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697774', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697802', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697830', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697858', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697886', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697914', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697942', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697970', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_697998', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698026', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698054', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698082', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698110', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698138', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698166', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698194', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698222', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698250', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698278', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698306', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698334', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698362', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698390', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698418', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698446', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698474', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_698502', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.999 | Q16 | What Small molecule therapies have been approved by the FDA to treat digestive system neuroendocrine neoplasm? | There are no drug Small molecule therapies approved to treat digestive system neuroendocrine neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "digestive system neuroendocrine neoplasm" OR LOWER(mesh_heading) = "digestive system neuroendocrine neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.884 | Q16 | What Small molecule therapies have been approved by the FDA to treat cerebral palsy? | There are 4 Small molecule therapy drugs that are approved to treat cerebral palsy which are as follows: Cyclobenzaprine Hydrochloride, Diazepam, Dantrolene Sodium, and Baclofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cerebral palsy" OR LOWER(mesh_heading) = "cerebral palsy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_151250', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151256', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151262', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151268', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151274', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151280', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151286', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151292', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151298', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151304', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151310', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151316', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151322', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151328', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151334', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151340', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151346', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151352', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151358', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151364', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151370', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151376', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151382', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151388', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151394', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151400', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151406', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151412', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151418', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151424', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151430', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_151436', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960192', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960211', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960230', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960249', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960268', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960287', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960306', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960325', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960344', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960363', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960382', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960401', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960420', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960439', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960458', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960477', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960496', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960515', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960534', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960553', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960572', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960591', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960610', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960629', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960648', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960667', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960686', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960705', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960724', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960743', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960762', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960781', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960800', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960819', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960838', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960857', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960876', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960895', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960914', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960933', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960952', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960971', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_960990', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961009', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961028', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961047', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961066', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961085', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961104', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961123', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961142', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961161', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961180', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961199', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961218', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961237', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961256', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961275', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961294', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961313', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961332', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961351', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961370', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961389', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961408', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961427', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961446', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}, {'UUID': 'DrugTargetsIndication121923_text_961465', 'drugName': 'Diazepam', 'tradeNames_list': "['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'DialarDialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensolDizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'SerenackSolis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'ValreleaseValtoco', 'Vivol']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.781 | Q16 | What Small molecule therapies have been approved by the FDA to treat aortic stenosis? | There are no drug Small molecule therapies approved to treat aortic stenosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aortic stenosis" OR LOWER(mesh_heading) = "aortic stenosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1228 | Q16 | What Small molecule therapies have been approved by the FDA to treat juvenile idiopathic arthritis? | There are 8 Small molecule therapy drugs that are approved to treat juvenile idiopathic arthritis which are as follows: Prednisone, Dexamethasone, Celecoxib, Naproxen Sodium, Naproxen, Ibuprofen, Meloxicam, and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "juvenile idiopathic arthritis" OR LOWER(mesh_heading) = "juvenile idiopathic arthritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217636', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_217844', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218052', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218260', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218468', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218676', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218884', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219092', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219300', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219508', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219716', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219924', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220132', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220340', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220548', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220756', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_226330', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_226615', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_226900', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_227185', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_227470', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_227755', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228040', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228325', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228610', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_228895', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_229180', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_229465', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_229750', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230035', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230320', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230605', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_230890', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_231175', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_231460', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_231745', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_232030', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_232315', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_832941', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_833052', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_833163', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_833274', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_833385', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_833496', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838045', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838062', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838079', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838096', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838113', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838130', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838147', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838164', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838181', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838198', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838215', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838232', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838249', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838266', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838283', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838300', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838332', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838373', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838414', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838455', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838496', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838537', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838578', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838619', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838660', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838701', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838742', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838783', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838824', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838865', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838906', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838947', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_838988', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839029', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839070', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839111', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839152', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839193', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839234', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839275', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839316', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839357', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839398', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839439', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839480', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839521', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839562', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839603', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839644', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839685', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839768', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839847', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_839926', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_840005', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_840084', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_840163', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1763 | Q16 | What Small molecule therapies have been approved by the FDA to treat xerostomia? | There are no drug Small molecule therapies approved to treat xerostomia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "xerostomia" OR LOWER(mesh_heading) = "xerostomia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.5 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat atherosclerosis? | Inclisiran Sodium is the only Oligonucleotide therapy approved by the FDA to treat atherosclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "atherosclerosis" OR LOWER(mesh_heading) = "atherosclerosis") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993739', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993741', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993743', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993745', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993747', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993749', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993751', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993753', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993755', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993757', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993759', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993761', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993763', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993765', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993767', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993769', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993771', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993773', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_993775', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1011 | Q16 | What Small molecule therapies have been approved by the FDA to treat dystonic disorder? | There are no drug Small molecule therapies approved to treat dystonic disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dystonic disorder" OR LOWER(mesh_heading) = "dystonic disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1707 | Q16 | What Small molecule therapies have been approved by the FDA to treat treatment resistant depression? | There are no drug Small molecule therapies approved to treat treatment resistant depression. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "treatment resistant depression" OR LOWER(mesh_heading) = "treatment resistant depression") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.265 | Q16 | What Protein therapies have been approved by the FDA to treat postpartum depression? | There are no drug Protein therapies approved to treat postpartum depression. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "postpartum depression" OR LOWER(mesh_heading) = "postpartum depression") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1567 | Q16 | What Small molecule therapies have been approved by the FDA to treat refractory anemia? | There are no drug Small molecule therapies approved to treat refractory anemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "refractory anemia" OR LOWER(mesh_heading) = "refractory anemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1610 | Q16 | What Small molecule therapies have been approved by the FDA to treat secondary Parkinson disease? | Amantadine Hydrochloride is the only Small molecule therapy approved by the FDA to treat secondary Parkinson disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "secondary parkinson disease" OR LOWER(mesh_heading) = "secondary parkinson disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_441022', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441036', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441050', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441064', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441078', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441092', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441106', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441120', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441134', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441148', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441162', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441176', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441190', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441204', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441218', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441232', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441246', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441260', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441274', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441288', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441302', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441316', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441330', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441344', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441358', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441372', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441386', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441400', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441414', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441428', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441442', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441456', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441470', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441484', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441498', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441512', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441526', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441540', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441554', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441568', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441582', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441596', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441610', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441624', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441638', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441652', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441666', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441680', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441694', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441708', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441722', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441736', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441750', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441764', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441778', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441792', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441806', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441820', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441834', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441848', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441862', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441876', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441890', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441904', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441918', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441932', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441946', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441960', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441974', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_441988', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442002', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442016', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442030', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442044', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442058', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442072', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442086', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442100', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442114', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442128', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442142', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442156', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442170', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442184', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442198', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442212', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442226', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442240', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442254', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442268', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442282', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442296', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442310', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442324', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442338', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442352', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442366', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442380', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442394', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}, {'UUID': 'DrugTargetsIndication121923_text_442408', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.447 | Q16 | What Small molecule therapies have been approved by the FDA to treat Gastrointestinal hemorrhage? | There are no drug Small molecule therapies approved to treat Gastrointestinal hemorrhage. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastrointestinal hemorrhage" OR LOWER(mesh_heading) = "gastrointestinal hemorrhage") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1010 | Q16 | What Small molecule therapies have been approved by the FDA to treat dysplasia of cervix? | There are no drug Small molecule therapies approved to treat dysplasia of cervix. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dysplasia of cervix" OR LOWER(mesh_heading) = "dysplasia of cervix") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1086 | Q16 | What Small molecule therapies have been approved by the FDA to treat frozen shoulder? | There are 6 Small molecule therapy drugs that are approved to treat frozen shoulder which are as follows: Prednisone, Triamcinolone Acetonide, Dexamethasone, Lidocaine, Naproxen Sodium, and Capsaicin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "frozen shoulder" OR LOWER(mesh_heading) = "frozen shoulder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217668', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_217876', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218084', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218292', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218500', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218708', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218916', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219124', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219332', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219540', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219748', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219956', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220164', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220372', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220580', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220788', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_221881', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_221946', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222011', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222076', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222141', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222206', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222271', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222336', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_226365', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_226650', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_226935', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_227220', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_227505', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_227790', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228075', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228360', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228645', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228930', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_229215', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_229500', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_229785', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230070', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230355', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230640', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230925', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_231210', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_231495', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_231780', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_232065', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_232350', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_637794', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_637909', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638024', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638139', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638254', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638369', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638484', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638599', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638714', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638829', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638944', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639059', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639174', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639289', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639404', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639519', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639634', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639749', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639864', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639979', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640094', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640209', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640324', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640439', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640554', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640669', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640784', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640899', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641014', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641129', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641244', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641359', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641474', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641589', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641704', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641819', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_641934', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642049', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642164', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642279', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642394', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642509', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642624', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642739', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642854', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_642969', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643084', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643199', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643314', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643429', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643544', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643659', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643774', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_643889', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.845 | Q16 | What Small molecule therapies have been approved by the FDA to treat breast carcinoma in situ? | There are no drug Small molecule therapies approved to treat breast carcinoma in situ. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "breast carcinoma in situ" OR LOWER(mesh_heading) = "breast carcinoma in situ") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1576 | Q16 | What Small molecule therapies have been approved by the FDA to treat respiratory system disease? | There are 2 Small molecule therapy drugs that are approved to treat respiratory system disease which are as follows: Nitric Oxide and Ivacaftor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "respiratory system disease" OR LOWER(mesh_heading) = "respiratory system disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974152', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974206', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974260', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974314', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974368', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974422', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974476', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974530', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974584', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974638', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974692', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974746', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974800', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974854', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974908', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_974962', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975016', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975070', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975124', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975178', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975232', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975286', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975340', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975394', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975448', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975502', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975556', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975610', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975664', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975718', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975772', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975826', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975880', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975934', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_975988', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976042', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976096', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976150', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976204', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976258', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976312', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976366', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976420', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976474', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976528', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976582', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976636', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976690', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976744', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976798', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976852', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976906', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_976960', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977014', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977068', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977122', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977176', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977230', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977284', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977338', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977392', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977446', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977500', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977554', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977608', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977662', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977716', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977770', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977824', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977878', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977932', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_977986', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978040', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978094', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978148', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978202', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978256', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978310', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978364', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978418', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978472', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978526', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978580', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978634', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978688', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978742', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978796', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978850', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978904', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_978958', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979012', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979066', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979120', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979174', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979228', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979282', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979336', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979390', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979444', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}, {'UUID': 'DrugTargetsIndication121923_text_979498', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.306 | Q16 | What Protein therapies have been approved by the FDA to treat thrombotic microangiopathy? | There are no drug Protein therapies approved to treat thrombotic microangiopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombotic microangiopathy" OR LOWER(mesh_heading) = "thrombotic microangiopathy") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1372 | Q16 | What Small molecule therapies have been approved by the FDA to treat neuroendocrine carcinoma? | There are no drug Small molecule therapies approved to treat neuroendocrine carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroendocrine carcinoma" OR LOWER(mesh_heading) = "neuroendocrine carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.315 | Q16 | What Protein therapies have been approved by the FDA to treat uterine fibroid? | There are no drug Protein therapies approved to treat uterine fibroid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "uterine fibroid" OR LOWER(mesh_heading) = "uterine fibroid") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.150 | Q16 | What Protein therapies have been approved by the FDA to treat dumping syndrome? | There are no drug Protein therapies approved to treat dumping syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dumping syndrome" OR LOWER(mesh_heading) = "dumping syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1157 | Q16 | What Small molecule therapies have been approved by the FDA to treat hyperemia? | There are no drug Small molecule therapies approved to treat hyperemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperemia" OR LOWER(mesh_heading) = "hyperemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1222 | Q16 | What Small molecule therapies have been approved by the FDA to treat irritable bowel syndrome? | There are 3 Small molecule therapy drugs that are approved to treat irritable bowel syndrome which are as follows: Eluxadoline, Tenapanor Hydrochloride, and Lubiprostone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "irritable bowel syndrome" OR LOWER(mesh_heading) = "irritable bowel syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763310', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763311', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763312', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763313', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763314', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763315', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763316', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763317', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763318', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763319', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763320', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763321', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763322', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763323', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763324', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763325', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763326', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763327', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763328', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763329', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763330', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763331', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763332', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763333', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763334', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763335', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763336', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763337', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763338', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763339', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763340', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763341', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763342', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763343', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763344', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763345', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763346', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763347', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763348', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_763349', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094304', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094308', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094312', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094316', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193386', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193391', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193396', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193401', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193406', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193411', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193416', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193421', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193426', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193431', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193436', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193441', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193446', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193451', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193456', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193461', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193466', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1193471', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.578 | Q16 | What Small molecule therapies have been approved by the FDA to treat Osteopenia? | There are no drug Small molecule therapies approved to treat Osteopenia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteopenia" OR LOWER(mesh_heading) = "osteopenia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.51 | Q16 | What Protein therapies have been approved by the FDA to treat MODY? | Liraglutide is the only Protein therapy approved by the FDA to treat MODY. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mody" OR LOWER(mesh_heading) = "mody") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044424', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044447', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044470', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044493', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044516', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044539', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044562', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044585', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044608', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044631', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044654', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044677', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044700', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044723', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044746', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044769', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044792', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044815', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044838', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044861', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044884', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044907', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044930', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044953', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044976', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1044999', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045022', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045045', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045068', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045091', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045114', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045137', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045160', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045183', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045206', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045229', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045252', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045275', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045298', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045321', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045344', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045367', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045390', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045413', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045436', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045459', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045482', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045505', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045528', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045551', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045574', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045597', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045620', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045643', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045666', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045689', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}, {'UUID': 'DrugTargetsIndication121923_text_1045712', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1569 | Q16 | What Small molecule therapies have been approved by the FDA to treat relapsing-remitting multiple sclerosis? | Siponimod Fumarate is the only Small molecule therapy approved by the FDA to treat relapsing-remitting multiple sclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "relapsing-remitting multiple sclerosis" OR LOWER(mesh_heading) = "relapsing-remitting multiple sclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1036785', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036788', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036791', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036794', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036797', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_1036800', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170989', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.732 | Q16 | What Small molecule therapies have been approved by the FDA to treat alcohol withdrawal? | There are no drug Small molecule therapies approved to treat alcohol withdrawal. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alcohol withdrawal" OR LOWER(mesh_heading) = "alcohol withdrawal") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.841 | Q16 | What Small molecule therapies have been approved by the FDA to treat brain injury? | Baclofen is the only Small molecule therapy approved by the FDA to treat brain injury. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brain injury" OR LOWER(mesh_heading) = "brain injury") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193124', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193149', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193174', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193199', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193224', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193249', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193274', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193299', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193324', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}, {'UUID': 'DrugTargetsIndication121923_text_1193349', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1124 | Q16 | What Small molecule therapies have been approved by the FDA to treat head and neck neoplasia? | There are no drug Small molecule therapies approved to treat head and neck neoplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "head and neck neoplasia" OR LOWER(mesh_heading) = "head and neck neoplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1175 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypothyroidism? | There are 2 Small molecule therapy drugs that are approved to treat hypothyroidism which are as follows: Fenofibrate and Levothyroxine Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypothyroidism" OR LOWER(mesh_heading) = "hypothyroidism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243941', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_243970', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_243999', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244028', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244057', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244086', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244115', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244144', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244173', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244202', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244231', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244260', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244289', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244318', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244347', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244376', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244405', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_244434', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924799', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924806', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924813', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924820', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924827', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924834', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924841', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924848', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924855', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924862', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924869', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924876', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924883', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924890', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924897', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924904', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924911', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924918', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924925', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924932', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924939', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924946', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924953', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924960', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924967', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924974', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924981', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924988', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924995', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925002', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925009', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925016', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925023', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925030', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925037', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925044', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925051', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925058', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925065', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925072', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925079', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925086', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925093', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925100', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925107', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925114', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925121', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925128', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925135', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925142', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925149', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925156', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925163', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925170', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925177', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925184', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925191', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925198', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925205', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925212', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925219', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925226', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925233', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925240', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925247', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925254', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925261', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925268', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925275', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925282', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925289', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925296', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925303', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925310', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925317', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925324', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925331', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925338', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925345', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925352', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925359', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925366', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.474 | Q16 | What Small molecule therapies have been approved by the FDA to treat Headache? | There are 4 Small molecule therapy drugs that are approved to treat Headache which are as follows: Acetaminophen, Aspirin, Naproxen, and Ibuprofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "headache" OR LOWER(mesh_heading) = "headache") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828732', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_828837', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_828942', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829047', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829152', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829257', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829362', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829467', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829572', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829677', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829782', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829887', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_829992', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830097', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830202', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830307', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830412', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830517', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830622', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830727', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830832', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_830937', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831042', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831147', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831252', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831357', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831462', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831567', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831672', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831777', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831882', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_831987', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832092', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832197', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832302', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832407', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832512', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832617', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832722', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_832827', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_833640', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_833797', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_833954', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_834111', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_834268', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_834425', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_834582', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_834739', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_834896', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_835053', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_835210', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_835367', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_835524', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_835681', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_835838', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_835995', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838326', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838367', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838408', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838449', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838490', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838531', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838572', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838613', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838654', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838695', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838736', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838777', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838818', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838859', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838900', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838941', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_838982', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839023', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839064', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839105', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839146', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839187', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839228', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839269', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839310', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839351', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839392', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839433', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839474', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839515', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839556', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839597', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839638', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839679', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839761', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839840', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839919', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_839998', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_840077', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_840156', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_840235', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_840314', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_840393', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}, {'UUID': 'DrugTargetsIndication121923_text_840472', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.979 | Q16 | What Small molecule therapies have been approved by the FDA to treat dermatitis? | Triamcinolone Acetonide is the only Small molecule therapy approved by the FDA to treat dermatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dermatitis" OR LOWER(mesh_heading) = "dermatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221888', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_221953', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_222018', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_222083', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_222148', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_222213', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_222278', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_222343', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.657 | Q16 | What Small molecule therapies have been approved by the FDA to treat Thromboembolism? | There are no drug Small molecule therapies approved to treat Thromboembolism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thromboembolism" OR LOWER(mesh_heading) = "thromboembolism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.402 | Q16 | What Small molecule therapies have been approved by the FDA to treat Craniopharyngioma? | There are no drug Small molecule therapies approved to treat Craniopharyngioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "craniopharyngioma" OR LOWER(mesh_heading) = "craniopharyngioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.515 | Q16 | What Small molecule therapies have been approved by the FDA to treat Intellectual disability? | There are no drug Small molecule therapies approved to treat Intellectual disability. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intellectual disability" OR LOWER(mesh_heading) = "intellectual disability") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.322 | Q16 | What Small molecule therapies have been approved by the FDA to treat AL amyloidosis? | There are 2 Small molecule therapy drugs that are approved to treat AL amyloidosis which are as follows: Tafamidis and Tafamidis Meglumine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "al amyloidosis" OR LOWER(mesh_heading) = "al amyloidosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097597', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097601', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097605', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097609', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097613', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097617', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097621', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097626', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097631', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097636', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097641', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'drugType': 'Small molecule', 'actionType': 'stabiliser', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.20 | Q16 | What Protein therapies have been approved by the FDA to treat Adenomyosis? | There are no drug Protein therapies approved to treat Adenomyosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adenomyosis" OR LOWER(mesh_heading) = "adenomyosis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.689 | Q16 | What Small molecule therapies have been approved by the FDA to treat Yersinia pestis infectious disease? | There are no drug Small molecule therapies approved to treat Yersinia pestis infectious disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "yersinia pestis infectious disease" OR LOWER(mesh_heading) = "yersinia pestis infectious disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.36 | Q16 | What Protein therapies have been approved by the FDA to treat Cushing syndrome? | There are no drug Protein therapies approved to treat Cushing syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cushing syndrome" OR LOWER(mesh_heading) = "cushing syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.910 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic bronchitis? | There are 9 Small molecule therapy drugs that are approved to treat chronic bronchitis which are as follows: Budesonide, Fluticasone Propionate, Roflumilast, Umeclidinium Bromide, Aclidinium Bromide, Ipratropium Bromide, Tiotropium Bromide, Olodaterol Hydrochloride, and Indacaterol Maleate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic bronchitis" OR LOWER(mesh_heading) = "chronic bronchitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222392', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222437', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222482', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222527', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222572', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222617', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222662', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222707', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222752', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222797', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222842', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222887', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222932', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_222977', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223022', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223067', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223112', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223157', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223202', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223247', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223292', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223337', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223382', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223427', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223472', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223517', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223562', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223607', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223652', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223697', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223742', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223787', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223832', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223877', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223922', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_223967', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224012', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224057', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224102', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224147', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224192', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224237', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224282', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224327', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224372', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224417', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224462', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224507', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224552', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224597', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224642', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224687', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224732', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224777', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224822', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224867', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224912', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_224957', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225002', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225047', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225092', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225137', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225182', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225227', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225272', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225317', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225362', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_225407', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232399', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232426', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232453', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232480', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232507', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232534', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232561', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232588', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232615', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232642', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232669', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232696', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232723', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232750', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232777', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232804', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232831', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232858', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232885', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232912', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232939', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232966', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_232993', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233020', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233047', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233074', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233101', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233128', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233155', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233182', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233209', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}, {'UUID': 'DrugTargetsIndication121923_text_233236', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.835 | Q16 | What Small molecule therapies have been approved by the FDA to treat brachial plexus neuritis? | There are no drug Small molecule therapies approved to treat brachial plexus neuritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brachial plexus neuritis" OR LOWER(mesh_heading) = "brachial plexus neuritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1581 | Q16 | What Small molecule therapies have been approved by the FDA to treat retinal vein occlusion? | There are no drug Small molecule therapies approved to treat retinal vein occlusion. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "retinal vein occlusion" OR LOWER(mesh_heading) = "retinal vein occlusion") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.410 | Q16 | What Small molecule therapies have been approved by the FDA to treat Diarrhea? | There are 2 Small molecule therapy drugs that are approved to treat Diarrhea which are as follows: Telotristat Etiprate and Crofelemer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diarrhea" OR LOWER(mesh_heading) = "diarrhea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097494', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000139287', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097495', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000139287', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097496', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000139287', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097497', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000139287', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097498', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000139287', 'approvedSymbol': 'TPH2', 'approvedName': 'tryptophan hydroxylase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097499', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129167', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097500', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129167', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097501', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129167', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097502', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129167', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1097503', 'drugName': 'Telotristat Etiprate', 'tradeNames_list': "['Xermelo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129167', 'approvedSymbol': 'TPH1', 'approvedName': 'tryptophan hydroxylase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1103254', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000001626', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1103258', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000001626', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1103262', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000001626', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1103266', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000131620', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1103270', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000131620', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1103274', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000131620', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.928 | Q16 | What Small molecule therapies have been approved by the FDA to treat cirrhosis of liver? | There are 2 Small molecule therapy drugs that are approved to treat cirrhosis of liver which are as follows: Ribavirin and Spironolactone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cirrhosis of liver" OR LOWER(mesh_heading) = "cirrhosis of liver") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937564', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_937565', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_937589', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_937590', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094353', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094391', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094429', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094467', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094505', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094543', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094581', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094619', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094657', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.